IDEV Technologies Names Veteran Healthcare Executive Dennis Donohoe, M.D. Chief Medical Officer

Provides Significant and Broad Expertise in Clinical Trials, Regulatory Affairs

WEBSTER, Texas, May 24, 2010 - IDEV Technologies, Incorporated, (IDEV) an emerging leader in the
development and marketing of minimally invasive medical technologies, today
announced that veteran healthcare executive Dennis Donohoe, M.D., has been
named Chief Medical Officer. Dr. Donohoe reports directly to President and
Chief Executive Officer Christopher Owens.

Dr. Donohoe worked in various capacities within Johnson & Johnson for 20
years, 11 of which were with the Cordis division. While with Cordis he had
worldwide responsibility for clinical research, encompassing coronary,
endovascular and neurovascular products. He ultimately served as Worldwide
Vice President of Clinical and Medical Affairs. Dr. Donohoe's expertise has
been influential in IDEV's clinical trial efforts, including SUPERB
(Comparison of the SUPERA PERipheral System to a Performance Goal Derived
from Balloon Angioplasty Clinical Trials in the Superficial Femoral Artery),
a prospective, single-arm trial of 258 patients at a variety of U.S. sites.

"I have worked closely with Dennis over the years and have seen
first-hand the value he brings to an organization," said Gary Ansel, M.D.,
Director, Center for Critical Limb Care, Riverside Methodist Hospital,
Columbus, Ohio. "In particular, he will be a major asset in the advancement
of IDEV's clinical trials, its relationships with the FDA and other
regulatory agencies worldwide."

At IDEV, Dr. Donohoe will manage the Company's clinical group and will
provide input to all of the clinical, regulatory and quality control
processes and strategies. His expertise will directly contribute to the
enhanced growth of the organization, Owens noted.

"Dennis is a world class leader, well known by many healthcare
professionals, including the FDA," Owens said. "He will help guide the
organization on regulatory and clinical strategies, encompassing both our
current and new clinical trials and the launches of our novel and proprietary
stent designs and delivery systems in the coming weeks and months. His
support and insight, based on his multifaceted professional and medical
experience, makes him an invaluable member of our team," Owens said.

Prior to Cordis, Dr. Donohoe worked for seven years at Ethicon where he
became Director of Medical Affairs. From 1989 to 1990 he was Associate
Director, Gastroenterology for Glaxo, Inc. From 1986 to 1989 he worked in
clinical research for McNeil Pharmaceuticals.

Dr. Donohoe is a magna cum laude graduate of LaSalle University and
received his M.D. from Milton S. Hershey Medical Center, Penn State
University. He did his internship and residency in Family Medicine at Bryn
Mawr Hospital.

About IDEV Technologies, Incorporated

IDEV Technologies, Incorporated (IDEV) is an innovator and developer of
next generation medical devices for use in the interventional radiology,
vascular surgery and cardiology device marketplace. IDEV's worldwide
headquarters is located in Webster, Texas and the European headquarters is
located in Beuningen, Netherlands.

    Contact:  Julie Nguyen, Marketing Communications Manager
              IDEV Technologies, Incorporated
              +1-281-525-2000

Julie Nguyen, Marketing Communications Manager of IDEV Technologies, Incorporated, +1-281-525-2000